×
About 6,525 results

ALLMedicine™ Hypokalemia Center

Research & Reviews  1,481 results

Severe hypophosphatemia as the initial presentation of renal Fanconi's syndrome and dis...
https://doi.org/10.1159/000527931
Kidney & Blood Pressure Research; Wu Y, Ma T et. al.

Nov 23rd, 2022 - Zoledronic acid (ZA) is a widely used bisphosphonate compound for the prevention of skeletal metastasis-associated osteolysis and treatment of post-menopause osteoporosis. Acute kidney injury is one of the commonly described renal complications. E...

Intraindividual variability of serum aldosterone and its implication for primary aldost...
https://doi.org/10.1210/clinem/dgac679
The Journal of Clinical Endocrinology and Metabolism; Maciel AAW, Freitas TC et. al.

Nov 23rd, 2022 - Primary aldosteronism (PA) screening relies on an elevated aldosterone to renin ratio with a minimum aldosterone level, which varies from 10 to 15 ng/dL (277 to 415.5 pmol/L) using immunoassay. To evaluate intraindividual coefficient of variation ...

Hypertension With Hypokalemia: A Quiz.
https://doi.org/10.1053/j.ajkd.2022.07.011
American Journal of Kidney Diseases : the Official Journa... Caruso BJ, Cotant CL et. al.

Nov 22nd, 2022 - Hypertension With Hypokalemia: A Quiz.|2022|Caruso BJ,Cotant CL,Mielke BA,Pfeiffer DC,|diagnosis,etiology,complications,diagnosis,

Image-guidance volume modulated arc radiotherapy concurrently with Nab-paclitaxel plus ...
https://doi.org/10.1016/j.ijrobp.2022.11.011
International Journal of Radiation Oncology, Biology, Phy... Jiang P, Deng X et. al.

Nov 20th, 2022 - Nanoparticle albumin-bound (nab)- paclitaxel has improved uptake by tumor cells in comparison to paclitaxel. The aim of this study was to determine the maximal tolerated dose (MTD) and the dose-limiting toxicity (DLT) of nab-paclitaxel plus cispla...

Safety of Withholding Perioperative Hydrocortisone for Patients With Pituitary Adenomas...
https://doi.org/10.1001/jamanetworkopen.2022.42221
JAMA Network Open; Guo X, Zhang D et. al.

Nov 17th, 2022 - Pituitary adenoma is the second most common primary brain tumor. Perioperative hydrocortisone has been used for decades to avoid postoperative adrenal insufficiency. Recent studies suggest that withholding perioperative hydrocortisone may be safe ...

see more →

Guidelines  1 results

Case detection, diagnosis, and treatment of patients with primary aldosteronism: an end...
https://doi.org/10.1210/jc.2008-0104
The Journal of Clinical Endocrinology and Metabolism; Funder JW, Carey RM et. al.

Jun 17th, 2008 - Our objective was to develop clinical practice guidelines for the diagnosis and treatment of patients with primary aldosteronism. The Task Force comprised a chair, selected by the Clinical Guidelines Subcommittee (CGS) of The Endocrine Society, si...

see more →

Drugs  629 results see all →

Clinicaltrials.gov  80 results

A Multicenter, Prospective, Non-interventional Cohort Study to Evaluate the Safety and Treatment Pattern of Sodium Zirconium Cyclosilicate for Hyperkalaemia Management in Real World Practice in China
https://clinicaltrials.gov/ct2/show/NCT05271266

Sep 30th, 2022 - Background/Rationale: Hyperkalaemia (HK) is a common electrolyte disturbance in clinical practice, defined as serum potassium (sK) beyond the normal range. The cut-off value for HK diagnosis is 5.0 mmol/L in most international guidelines[1, 2]. HK...

Application of 68Ga-Pentixafor PET/CT in Primary Aldosteronism and Pre-postoperative of SAAE
https://clinicaltrials.gov/ct2/show/NCT05188872

Jul 28th, 2022 - Primary aldosteronism: Hypertension is divided into primary hypertension and secondary hypertension. Secondary hypertension refers to hypertension with clear etiology. When the etiology is identified and effectively removed or controlled, hyperten...

Diuretic Tuner Clinical Decision Support
https://clinicaltrials.gov/ct2/show/NCT04759274

Jul 26th, 2022 - Study Population: 30 subjects with signs of hypervolemia and either nephrotic syndrome or chronic kidney disease 4 to 5. Study Intervention: This is a nonrandomized, uncontrolled trial. The Diuretic Tuner mobile device application will be deployed...

Fluconazole in Hypercalciuric Patients With Increased 1,25(OH)2D Levels
https://clinicaltrials.gov/ct2/show/NCT04495608

Jul 6th, 2022 - Hypercalciuria is one of the most frequent metabolic disorders associated with nephrolithiasis and/or nephrocalcinosis leading to Chronic Kidney Disease (CKD) and bone complications in adults. Hypercalciuria can be secondary to increased intestina...

Comparison of a Low Dose to a Standard Dose of Insulin in Adult DKA in ICU to Reduce Metabolic Complications
https://clinicaltrials.gov/ct2/show/NCT05443802

Jul 5th, 2022 - Diabetic ketoacidosis (DKA), a frequent complication of diabetes, is the consequence of a profound insulin deficiency responsible for osmotic polyuria which leads to major losses of water, sodium and potassium as well as the generation of metaboli...

see more →

News  415 results

FDA Approves Additional Dosing Schedule for Rylaze in ALL and LBL
https://www.onclive.com/view/fda-approves-additional-intramuscular-dosing-schedule-for-rylaze-in-all-and-lbl

Nov 18th, 2022 - The FDA has approved a supplemental biologics license application to add a Monday/Wednesday/Friday (MWF) intramuscular dosing schedule for asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze).1 In June 2021, Rylaze was approved for use a...

Electrolyte Disturbances a Harbinger of Eating Disorders?
https://www.medscape.com/viewarticle/984087

Nov 15th, 2022 - Electrolyte abnormalities may serve as a precursor to a future eating disorder diagnosis, a finding that may help pinpoint candidates for screening. Researchers found that adolescents and adults with electrolyte abnormalities on routine outpatient...

HCTZ vs Chlorthalidone -- A Win for Practicing Doctors and Science
https://www.medscape.com/viewarticle/983614

Nov 5th, 2022 - U.S. experts favor chlorthalidone over hydrochlorothiazide (HCTZ) in the first-line treatment of hypertension. Yet practicing doctors are approximately 20-fold more likely to choose HCTZ over chlorthalidone.  During the opening late-breaking clini...

Telisotuzumab Vedotin Plus Erlotinib Shows Encouraging Activity in Advanced c-Met+ NSCLC
https://www.onclive.com/view/telisotuzumab-vedotin-plus-erlotinib-shows-encouraging-activity-in-advanced-c-met-nsclc

Nov 1st, 2022 - Telisotuzumab vedotin (teliso-V) in combination with erlotinib (Tarceva) induced promising outcomes in patients with advanced, EGFR-mutated, c-MET-positive non–small cell lung cancer (NSCLC) who were contraindicated for surgery or other approved t...

Cilta-Cel Induces Strong Response in Chinese Patients With Relapsed/Refractory Multiple Myeloma
https://www.onclive.com/view/cilta-cel-induces-strong-response-in-chinese-patients-with-relapsed-refractory-multiple-myeloma

Oct 28th, 2022 - Ciltacabtagene autoleucel (cilta-cel; Carvykti) produced early, deep, and durable responses in patients with relapsed/refractory multiple myeloma (RRMM) treated at 8 sites in China.1 Investigators said the results from the pivotal phase 2 CARTIFAN...

see more →

Patient Education  4 results see all →